申请人:COGNITION THERAPEUTICS, INC.
公开号:US20170197977A9
公开(公告)日:2017-07-13
This invention relates to novel diarylamino compounds that bind to the sigma-2 receptor, to pharmaceutical compositions comprising such compounds, and to methods for inhibiting or restoring synapse loss in neuronal cells, modulating a membrane trafficking change in neuronal cells, and treating cognitive decline and neurodegenerative diseases and disorders therewith.
这项发明涉及与sigma-2受体结合的新型二芳胺化合物,包括这种化合物的药物组合物,以及用于抑制或恢复神经元细胞中突触丢失,调节神经元细胞中膜运输变化,并用于治疗认知衰退和神经退行性疾病和障碍的方法。